Navigation Links
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Date:1/20/2010

onse to oral glucose tolerance testing as compared to patients receiving placebo (p<0.001 for both dose groups), as measured by area under the curve (AUC).  Consistent with the mechanism of action of LX4211, there was also a significant, dose-dependent increase in 24-hour urinary glucose excretion throughout the study period relative to placebo in both dose groups (p<0.001 at all time points measured).

With respect to broader metabolic and cardiovascular safety parameters, patients in both dose groups showed weight reduction accompanied by decreased blood pressure and triglycerides relative to placebo.  LX4211 demonstrated a favorable safety profile in the study with no dose-limiting toxicities.  Adverse events were generally mild and equally distributed across all groups, including the placebo group.

"The magnitude and rapid response in glycemic control, combined with the triglyceride reduction, may distinguish LX4211 from other agents in this class," said Dr. Brian Zambrowicz, chief scientific officer of Lexicon.  "We now believe that the action of LX4211 cannot be entirely explained by glucose excretion in the urine alone, but may also relate to secondary events that both further enhance glycemic control and provide the other metabolic improvements we have witnessed in this study."

In addition to LX4211, Lexicon has three additional drug candidates progressing through Phase 2 clinical trials: LX1032, a peripherally-available serotonin synthesis inhibitor for carcinoid syndrome; LX2931, an S1P lyase inhibitor for rheumatoid arthritis; and LX1031, a locally-acting serotonin synthesis inhibitor for irritable bowel syndrome, which recently completed a Phase 2a clinical tr
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
3. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
4. Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
7. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
8. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Pa. , Sept. 2, 2015 ... increases, diversifies revenue base with highly profitable specialty ... , Near-term growth potential with 11 product ... include Paragraph IV certifications  , Provides medium ... candidates in development, including eight controlled substances ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced ... UK - November 19-20, 2015)" conference to their ... cover industry case studies, regulatory updates, latest therapies and ... Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar Pharma ...
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... When looking at the types of people ... into one of two categories: those that have a weak appetite or those that have ... still want to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. ...
(Date:9/3/2015)... ... 03, 2015 , ... Leading post-acute electronic medical record (EMR) ... joining the company’s executive leadership team as VP of Product and as VP ... healthcare product and project management. He has been with HealthWyse since 2000 in ...
(Date:9/2/2015)... ... , ... The Aspen Clinic (TAC), located in Basalt, Colorado, today ... inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, Executive Director ... to fitness - we are much more than a gym. Our fitness and ...
(Date:9/2/2015)... ... 03, 2015 , ... Each year, the editors of Modern ... activists, corporate executives, entrepreneurs, health care professionals, and others have had the most ... magazine to tap the National League for Nursing’s outspoken CEO, Beverly Malone ...
(Date:9/2/2015)... ... 2015 , ... Healthegy, a leading producer of conferences, podcasts ... deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ) ... Larry Renfro, CEO of Optum, will deliver the morning address. In his post, ...
Breaking Medicine News(10 mins):Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3
... a colourless, odourless and tasteless chemical element - could ... ,Patients with chronic obstructive pulmonary disease (COPD) have ... the lungs at the end of each breath. This ... reasons for shortness of breath experienced by these patients, ...
... Here’s the good news, the bad news, and some more ... Americans, according to one recent study) are satisfied// with their ... way of having a good sex life, from prescription medication ... ,In many cases, physicians can work with their patients to ...
... Andhra Pradesh and Tamil Nadu will upgrade their existing ... ,"It has been decided to upgrade the hospitals in ... Vice Admiral surgeon Vijay K. Singh, director general of ... ,Singh said a Rs.3-billion budget has been sanctioned, ...
... one in three children in California is overweight or at ... health insurance company.// ,There are even more ... satellite cities. ,The number of overweight children ... rest of California, and nearly doubles the national rate, said ...
... Jammu and Kashmir by humanitarian group Médecins Sans Frontières (MSF) ... and more than one in 10 had been victims of ... ,The report by the Holland-based MSF is based on ... in mid-2005. The survey group defined 1989 as the beginning ...
... have made a Startling discovery. The researchers who want ... their intake of calories is restricted have found that ... on longevity in the fruit flies. ,Scientists ... increase the lifespan of many species, but the mechanism ...
Cached Medicine News:Health News:Helium Helps COPD Sufferers to Exercise 2Health News:Health Issues That Can Impact Sexual Satisfaction 2Health News:Health Issues That Can Impact Sexual Satisfaction 3Health News:Health Issues That Can Impact Sexual Satisfaction 4Health News:South India to Have Modern Military Hospitals 2Health News:Mental Health of Kashmiris Needs Urgent Attention: Survey 2Health News:Food Odors Linked With Lifespan in Fruit Flies 2Health News:Food Odors Linked With Lifespan in Fruit Flies 3Health News:Food Odors Linked With Lifespan in Fruit Flies 4Health News:Food Odors Linked With Lifespan in Fruit Flies 5
... With the increase in Endoscopic cases it is ... Monitor with the Surgical Light. This combination ... without having to adopt an uncomfortable pose. ... including the NUVO Monitoring System. As such ...
... This configuration offers all the performance of a ... perfectly for use in Outpatient Settings, Minor Procedure ... Mounting two single lights either side of the ... in a General OR when combining Flat Screen ...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously....
Medicine Products: